BNTX vs ZLAB: fair value comparison
BioNTech SE and Zai Lab Limited · Updated 2026-10-19
BNTX reports in EUR, so no same-currency fair-value verdict is published for it. ZLAB has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, ZLAB currently ranks higher by quality score. ZLAB carries the stronger quality grade.
| BNTX | ZLAB | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $96.85 | $23.19 |
| 12-month range | $83.89–$119.34 | $16.30–$28.02 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #127 of 301 Healthcare | #125 of 301 Healthcare |
| Quality grade | D | C |
| Leverage | Low | Low |
| Margin trend | Contracting | Contracting |
| Revenue growth | Declining | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: BNTX fair value analysis · ZLAB fair value analysis